These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 15922116

  • 1. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S, Nakamura K, Inoue H.
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 3. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
    Nakamura K, Yamagishi S, Matsui T, Inoue H.
    Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
    [Abstract] [Full Text] [Related]

  • 4. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S, Matsui T, Sato T, Takeuchi M.
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U.
    Int J Cardiol; 2006 Feb 08; 107(1):11-20. PubMed ID: 16337493
    [Abstract] [Full Text] [Related]

  • 6. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN.
    Gastroenterology; 2001 Apr 08; 120(5):1183-92. PubMed ID: 11266382
    [Abstract] [Full Text] [Related]

  • 7. Diabetes mellitus, obesity, and hepatic steatosis.
    Youssef W, McCullough AJ.
    Semin Gastrointest Dis; 2002 Jan 08; 13(1):17-30. PubMed ID: 11944630
    [Abstract] [Full Text] [Related]

  • 8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 08; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 9. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC, Berk PD.
    Semin Liver Dis; 2008 Nov 08; 28(4):407-26. PubMed ID: 18956297
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA.
    Am J Gastroenterol; 2001 Oct 08; 96(10):2957-61. PubMed ID: 11693332
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH.
    Hepatology; 2004 Jan 08; 39(1):188-96. PubMed ID: 14752837
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.